Drug Trial Radar · NCT04755283
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,287
Actual
Start
Feb 2, 2021
Primary completion
Feb 15, 2024
Study completion Dec 29, 2028
Sponsor
- Lead sponsor
- Anthos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Feb 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Conditions
- Atrial Fibrillation (AF)
- Stroke
Interventions
AbelacimabBiological
Abelacimab provided as liquid in vial (150 mg/mL)
RivaroxabanDrug
Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding EventsTime frame: Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
Locations
92 sites in 7 countries. Site status is shown where the registry gives one.
Anthos Investigative Site
Huntsville, Alabama
Anthos Investigative Site
Mobile, Alabama
Anthos Investigative Site
Stamford, Connecticut
Anthos Investigative Site
Clearwater, Florida
Anthos Investigative Site
Daytona Beach, Florida
Anthos Investigative Site
Largo, Florida
Anthos Investigative Site
Safety Harbor, Florida
Anthos Investigative Site
Saint Augustine, Florida
Anthos Investigative Site
Johns Creek, Georgia
Anthos Investigative Site
Owensboro, Kentucky
Anthos Investigative Site
Baltimore, Maryland
Anthos Investigative Site
Salisbury, Maryland
Anthos Investigative Site
Framingham, Massachusetts
Anthos Investigative Site
Haverhill, Massachusetts
Anthos Investigative Site
Lansing, Michigan
Anthos Investigative Site
Sewell, New Jersey
Anthos Investigative Site
Poughkeepsie, New York
Anthos Investigative Site
Southampton, New York
Anthos Investigative Site
Lenoir, North Carolina
Anthos Investigative Site
Fargo, North Dakota
Anthos Investigative Site
Oklahoma City, Oklahoma
Anthos Investigative Site
Camp Hill, Pennsylvania
Anthos Investigative Site
Kingsport, Tennessee
Anthos Investigative Site
Kingwood, Texas
Anthos Investigative Site
Odessa, Texas
Anthos Investigative Site
Tomball, Texas
Anthos Investigative Site
Falls Church, Virginia
Anthos Investigative Site
Manassas, Virginia
Anthos Investigative Site
Cambridge, Ontario, Canada
Anthos Investigative Site
Greater Sudbury, Ontario, Canada
Anthos Investigative Site
Oshawa, Ontario, Canada
Anthos Investigative Site
Greenfield Park, Quebec, Canada
Anthos Investigative Site
Montreal, Quebec, Canada
Anthos Investigative Site
Brandýs nad Labem, Central Bohemia, Czechia
Anthos Investigative Site
Poděbrady, Central Bohemia, Czechia
Anthos Investigative Site
Příbram, Central Bohemia, Czechia
Anthos Investigative Site
Slaný, Central Bohemia, Czechia
Anthos Investigative Site
Mariánské Lázně, KA, Czechia
Anthos Investigative Site
Trutnov, KR, Czechia
Anthos Investigative Site
Liberec, LB, Czechia
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.